Stereotaxis adds Shifrin, Holm to senior exec team

Stereotaxis has appointed Kevin Shifrin, as Stereotaxis’ new senior vice president of global marketing and business development; and Magnus Holm, PhD, as the new general manager for Europe.

Both Shifrin and Holm will report to Michael P. Kaminski, president and chief operating officer, according to the company.

Shifrin joins Stereotaxis from C.R. Bard, a developer, manufacturer and marketer of healthcare products in the fields of vascular, urology, oncology and surgical specialty products, where he served as vice president of global marketing for the peripheral vascular division.  He joined Bard in 2002 from Cordis, a subsidiary of Johnson & Johnson, where he served as the executive director of Marketing for Cordis Cardiology Europe, and helped oversee the execution of European marketing programs supporting the Cordis stent business. 

Holm joins Stereotaxis from Biosense Webster, a leader in technological advancements for the diagnosis and treatment of cardiac arrhythmias, where he served most recently as vice president of Europe, Middle East and Asia (EMEA), responsible for sales and marketing and business development throughout the EMEA region.

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.